Clinical Trial Detail

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Complete title: ADVL1721, A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma

Research Study Number	ADVL1721
Principal Investigator	Julie Park, MD
Phase	I/II

Look up trial at NIH

Research Study Description

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number	ADVL1721
Contact	Advanced Therapeutics Study Line
Telephone	206/987-2553
E-mail

Keywords: Neoplasms, Complex and Mixed; Neoplasms, Malignant

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019